Polyrizon announces initiation of preclinical studies for Benzodiazepines

Polyrizon (PLRZ) announced the initiation of preclinical studies for intranasal Benzodiazepines, a first-line treatment for acute repetitive seizures and status epilepticus, using its proprietary drug delivery platform. The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board. “Launching this preclinical program marks an important milestone in our initiative to improve emergency treatment options for epilepsy patients,” said Tomer Izraeli, CEO of Polyrizon. “We believe our intranasal delivery platform has the potential to offer a faster, safer and more accessible solution for managing acute seizures outside of clinical settings.”